UBS AM
DNA icon

UBS AM’s Ginkgo Bioworks DNA Stock Holding History

UBS AM’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$647K Buy
65,275
+698
+1% +$5.84K ﹤0.01% 2473
2026
Q1 		$396K Buy
64,577
+6,841
+12% +$56.9K ﹤0.01% 2599
2025
Q4 		$480K Buy
57,736
+60
+0.1% +$646 ﹤0.01% 2328
2025
Q3 		$841K Sell
57,676
-24,323
-30% -$291K ﹤0.01% 2061
2025
Q2 		$922K Buy
81,999
+37,735
+85% +$292K ﹤0.01% 2401
2025
Q1 		$252K Buy
44,264
+2,269
+5% +$23.1K ﹤0.01% 2566
2024
Q4 		$412K Buy
41,995
+5,746
+16% +$49.2K ﹤0.01% 2582
2024
Q3 		$295K Sell
36,249
-11,291
-24% -$113K ﹤0.01% 2731
2024
Q2 		$635K Buy
47,540
+11,729
+33% +$350K ﹤0.01% 2557
2024
Q1 		$1.66M Hold
35,811
– – ﹤0.01% 1771
2023
Q4 		$2.42M Buy
35,811
+1,820
+5% +$111K ﹤0.01% 1591
2023
Q3 		$2.46M Buy
33,991
+4,484
+15% +$358K ﹤0.01% 1520
2023
Q2 		$1.57M Hold
29,507
– – ﹤0.01% 1780
2023
Q1 		$1.57M Hold
29,507
– – ﹤0.01% 1780
2022
Q4 		$1.99M Buy
29,507
+6,939
+31% +$638K ﹤0.01% 1526
2022
Q3 		$2.82M Sell
22,568
-4,985
-18% -$594K ﹤0.01% 1420
2022
Q2 		$2.62M Buy
+27,553
New +$3.36M ﹤0.01% 1504

Other funds holding DNA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JMFC
J.M. Forbes & Co Boston, Massachusetts $1.27B AUM 26.46% 1-Year Est. Return

UBS AM's DNA Position: Q2 2026 in Review

UBS AM increased its Ginkgo Bioworks (DNA) stake by 1.1% in Q2 2026, buying an estimated $5.84K and bringing the position to 65,275 shares worth $647K. The position accounts for ﹤0.01% of the portfolio, ranked #2473.

UBS AM first reported a position in DNA in Q2 2022 and has held it in 17 quarters since. The position peaked at $2.82M in Q3 2022. 184 funds tracked by Wall St. Rank hold DNA as of Q2 2026.

  • UBS AM held 65,275 shares of Ginkgo Bioworks worth $647K as of Q2 2026.
  • UBS AM bought 698 Ginkgo Bioworks shares in Q2 2026, an estimated $5.84K.
  • Ginkgo Bioworks made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #2473 holding.
  • UBS AM first reported a position in Ginkgo Bioworks in Q2 2022 and has held it in 17 quarters since.
  • UBS AM's Ginkgo Bioworks position peaked at $2.82M in Q3 2022.
  • 184 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.